These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24892810)

  • 41. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantifying Anti-HIV Envelope-Specific Antibodies in Plasma from HIV Infected Individuals.
    Kant S; Zhang N; Routy JP; Tremblay C; Thomas R; Szabo J; Côté P; Trottier B; LeBlanc R; Rouleau D; Harris M; Dupuy FP; Bernard NF
    Viruses; 2019 May; 11(6):. PubMed ID: 31141927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.
    Bonsignori M; Wiehe K; Grimm SK; Lynch R; Yang G; Kozink DM; Perrin F; Cooper AJ; Hwang KK; Chen X; Liu M; McKee K; Parks RJ; Eudailey J; Wang M; Clowse M; Criscione-Schreiber LG; Moody MA; Ackerman ME; Boyd SD; Gao F; Kelsoe G; Verkoczy L; Tomaras GD; Liao HX; Kepler TB; Montefiori DC; Mascola JR; Haynes BF
    J Clin Invest; 2014 Apr; 124(4):1835-43. PubMed ID: 24614107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.
    Morris CD; Azadnia P; de Val N; Vora N; Honda A; Giang E; Saye-Francisco K; Cheng Y; Lin X; Mann CJ; Tang J; Sok D; Burton DR; Law M; Ward AB; He L; Zhu J
    mBio; 2017 Feb; 8(1):. PubMed ID: 28246356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
    Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
    J Virol; 2017 May; 91(9):. PubMed ID: 28202762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals.
    Carrillo J; Molinos-Albert LM; Rodríguez de la Concepción ML; Marfil S; García E; Derking R; Sanders RW; Clotet B; Blanco J
    PLoS One; 2015; 10(3):e0120648. PubMed ID: 25803681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.
    Sundling C; Li Y; Huynh N; Poulsen C; Wilson R; O'Dell S; Feng Y; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    Sci Transl Med; 2012 Jul; 4(142):142ra96. PubMed ID: 22786681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities.
    Seaton KE; Ballweber L; Lan A; Donathan M; Hughes S; Vojtech L; Moody MA; Liao HX; Haynes BF; Galloway CG; Richardson BA; Karim SA; Dezzutti CS; McElrath MJ; Tomaras GD; Hladik F
    PLoS One; 2014; 9(7):e101863. PubMed ID: 25054205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neutralization breadth and potency of serum derived from recently human immunodeficiency virus type 1-infected Thai individuals.
    Chaitaveep N; Utachee P; Chuenchitra T; Karasavvan N; Takeda N; Kameoka M
    Microbes Infect; 2016 May; 18(5):346-53. PubMed ID: 26774333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
    Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
    J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.
    Richard J; Pacheco B; Gohain N; Veillette M; Ding S; Alsahafi N; Tolbert WD; Prévost J; Chapleau JP; Coutu M; Jia M; Brassard N; Park J; Courter JR; Melillo B; Martin L; Tremblay C; Hahn BH; Kaufmann DE; Wu X; Smith AB; Sodroski J; Pazgier M; Finzi A
    EBioMedicine; 2016 Oct; 12():208-218. PubMed ID: 27633463
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
    Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
    Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
    Gardner MR; Fellinger CH; Prasad NR; Zhou AS; Kondur HR; Joshi VR; Quinlan BD; Farzan M
    J Virol; 2016 Sep; 90(17):7822-32. PubMed ID: 27334589
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies.
    Pujanauski LM; Janoff EN; McCarter MD; Pelanda R; Torres RM
    Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1422-7. PubMed ID: 23288906
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
    Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity.
    Samuelsson A; Broström C; van Dijk N; Sönnerborg A; Chiodi F
    Virology; 1997 Nov; 238(2):180-8. PubMed ID: 9400591
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
    Trott M; Weiβ S; Antoni S; Koch J; von Briesen H; Hust M; Dietrich U
    PLoS One; 2014; 9(5):e97478. PubMed ID: 24828352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.
    Johansson SE; Rollman E; Chung AW; Center RJ; Hejdeman B; Stratov I; Hinkula J; Wahren B; Kärre K; Kent SJ; Berg L
    Viral Immunol; 2011 Oct; 24(5):359-68. PubMed ID: 21958370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.
    Malherbe DC; Pissani F; Sather DN; Guo B; Pandey S; Sutton WF; Stuart AB; Robins H; Park B; Krebs SJ; Schuman JT; Kalams S; Hessell AJ; Haigwood NL
    J Virol; 2014 Nov; 88(22):12949-67. PubMed ID: 25210191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.